Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13453646 | 0.90 | HRH4 (0.37) | FLT3SIGMAR1ALDH1A1HRH4HRH3 | |
| SCHEMBL13469513 | 0.83 | DPP4 (0.36) | FLT3SIGMAR1HRH4HRH3 | |
| SCHEMBL19732396 | 0.79 | FLT3 (0.49) | FLT3SIGMAR1KDM4EALDH1A1HRH4 | |
| SCHEMBL23318249 | 0.78 | HRH3 (0.51) | SIGMAR1ALDH1A1IRAK4HRH4HRH3 | |
| SCHEMBL19732400 | 0.76 | SMN1; SMN2 (0.48) | KDM4EALDH1A1IRAK4SMN1; SMN2 | |
| SCHEMBL15133214 | 0.75 | NR5A2 (0.45) | SIGMAR1ALDH1A1HRH3 | |
| SCHEMBL19726585 | 0.75 | FLT3 (0.46) | FLT3SIGMAR1HRH4HRH3SMN1; SMN2 | |
| SCHEMBL19400545 | 0.74 | HRH4 (0.35) | IRAK4HRH4HRH3 | |
| SCHEMBL13453642 | 0.74 | SMPD1 (0.41) | HRH4HRH3 | |
| SCHEMBL23318555 | 0.74 | KMT2A (0.35) | KDM4EALDH1A1HRH4HRH3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316017-B2 | COT modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20100179123-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | FLT3 1327/4885SIGMAR1 978/4885KDM4E 1288/4885 |
| US-10316017-B2 | COT modulators and methods of use thereof | BRDT, THRB, HCCS | FLT3 1327/4885SIGMAR1 978/4885KDM4E 1288/4885 |
| US-20100179123-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | AURKA, AURKB, AURKC | FLT3 196/4885SIGMAR1 4423/4885KDM4E 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.